Using a special method to enhance cancer immunotherapy with localized treatments
Localized immunotherapy using alum-binding therapeutics
This study is exploring a new way to help your immune system fight cancer by using a special method that delivers helpful agents directly to tumors, aiming to make treatment more effective and less harsh on your body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10906932 on NIH RePORTER |
What this research studies
This research investigates a novel approach to cancer immunotherapy by using a technique that binds immune-boosting agents to aluminum hydroxide, a common adjuvant. By delivering these agents directly into tumors, the goal is to enhance their effectiveness while reducing side effects associated with systemic treatments. The study focuses on optimizing the retention of these agents at the tumor site to stimulate a strong immune response against cancer. Patients may benefit from a more targeted and less toxic treatment option compared to traditional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with localized tumors who are seeking innovative immunotherapy options.
Not a fit: Patients with advanced metastatic cancer or those who do not have tumors suitable for localized treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments that harness the body's immune system.
How similar studies have performed: Other research has shown promise in localized immunotherapy approaches, suggesting potential for success with this novel method.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Irvine, Darrell J — Massachusetts Institute of Technology
- Study coordinator: Irvine, Darrell J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.